Milan, 24 April 2020 - The IFCC, the international leading organization in the field of Clinical Chemistry and Laboratory Medicine, is pleased to announce that Prof. Nader RIFAI (Department of Laboratory Medicine, Boston Children’s Hospital, US), has been selected to receive the 2020 IFCC Howard Morris Distinguished Clinical Chemist Award, sponsored by Yashraj Biotechnology Ltd. This award, honouring IFCC President Prof. Howard Morris, recognizes specifically an individual who has made outstanding contributions to the science of Clinical Chemistry and Laboratory Medicine or the application of Clinical Chemistry to the understanding or the solution of medical problems.
The IFCC is very pleased to acknowledge the support from Yashraj Biotechnology Ltd in the recognition of scientists and educators with a distinguished career in this area.
Prof. Rifai is Professor of Pathology at Harvard Medical School, the Louis Joseph Gay-Lussac Chair in Laboratory Medicine, and the Director of Clinical Chemistry at Boston Children’s Hospital. Dr. Rifai received his PhD in Pathology from the Medical College of Virginia and his post-doctoral training in clinical chemistry was accomplished at the University in North Carolina in Chapel Hill. For more than two decades, Dr. Rifai’s research has concerned biomarkers of cardiovascular disease. Dr. Rifai’s work has also changed the practice of clinical chemistry, moving the FDA to clear several high sensitivity CRP assays for clinical use. He represented the U.S. clinical chemistry community in the CDC-sponsored international effort to standardize the CRP assay, and to participate in writing the new CDC/AHA-sponsored national guidelines for the use of inflammatory markers in cardiovascular disease. He published extensively. He created the Clinical Chemistry Trainee Council, a web-based, and free of charge educational program for trainees and mentors in laboratory medicine. As Editor of the current edition of the Tietz Textbook of Clinical Chemistry, he is pioneering a modern experience to textbook publishing and usage by linking the textbook to cloud-based electronic learning tools.
Prof. Maurizio FERRARI, IFCC President and Chair IFCC Awards Committee, said: "We are delighted in selecting Professor Nader Rifai for the 2020 IFCC Distinguished Clinical Chemist Award. He has a remarkable career in the field of clinical chemistry and laboratory medicine, and his efforts in delivering education in laboratory medicine by tailoring contents and formats effective for individuals across different stages of career and across the globe is unprecedented. I really believe that Dr Rifai is a most worthy recipient of the IFCC 2020 Distinguished Clinical Chemist Award”.
The 2020 IFCC Awardees are a witness of the contribution that IFCC gives to advancement of excellence in laboratory medicine for better healthcare worldwide. Doctor Rifai, along with nine other IFCC Distinguished Award winners will be formally announced on Wednesday 6th January 2021 at the Opening Ceremony of the 24th WorldLab - IFCC International Congress in Clinical Chemistry and Laboratory Medicine to be held in Seoul (South Korea) from 6th to 10th January 2021.
- end -
Click here to download the press release
IFCC is the leading organization in the field of Clinical Chemistry and Laboratory Medicine worldwide. Through leadership and innovation in science and education, IFCC strives to enhance the scientific level and the quality of diagnosis and therapy for patients throughout the world. IFCC builds on the professionalism of its members to provide quality services to patients. IFCC is a Federation of 93 Full Member and 17 Affiliate member Societies of Clinical Chemistry and Laboratory Medicine representing more than 45.000 individual clinical chemists, laboratory scientists, and laboratory physicians and 48 Corporate Members covering the major areas of clinical laboratory developments. For further details please contact: email@example.com.
ABOUT Yashraj Biotechnology Ltd
We are a research and innovation driven, ISO 13485:2016, ISO 9001:2015 and OHSAS 18001:2007 certified company, established in 1999 at Navi Mumbai, Maharashtra, India. We have operations in Germany, USA and will soon establish presence in South Korea. Our research, development and production-related activities encompass a whole range of native, recombinant and cell-derived antigens; and monoclonal antibodies. Highest standards of quality and unwavering commitment towards healthcare innovation have enabled us to capture some of the biggest market segments for various biomarker antigens and antibodies. Visit: https://www.yashraj.com/